FLT3LG
FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
Overview
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs).
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Crenolanib, Ponatinib, Sunitinib and Lestaurtinib and others. Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.82, affected pathway 0.83, animal model 0.41, genetic association 0.00).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
- 1 · What it is
FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
- 2 · What goes wrong in cancer
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins.
- 3 · How drugs use it
No product in this corpus aims at FLT3LG yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:3766 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49771 (protein name, function text, keywords and locations (REST API)); CIViC gene FLT3LG (2 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000090554 (association with cancer (MONDO_0004992) 0.53; (GraphQL API, CC0))
Biology
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs). Location: Cell membrane; Secreted (UniProt). Locus 19q13.33 (HGNC).
- Acute myeloid leukaemia: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 11 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FLT3LG" OR ABSTRACT:"FLT3LG" OR TITLE:"fms related receptor tyrosine kinase 3 ligand" OR ABSTRACT:"fms related receptor tyrosine kinase 3 ligand" OR TITLE:"Fms-related tyrosine kinase 3 ligand" OR ABSTRACT:"Fms-related tyrosine kinase 3 ligand") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FLT3LG, not a curated reading list.